Cargando…
Developing preclinical models of neuroblastoma: driving therapeutic testing
Despite advances in cancer therapeutics, particularly in the area of immuno-oncology, successful treatment of neuroblastoma (NB) remains a challenge. NB is the most common cancer in infants under 1 year of age, and accounts for approximately 10% of all pediatric cancers. Currently, children with hig...
Autores principales: | Ornell, Kimberly J., Coburn, Jeannine M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7422585/ https://www.ncbi.nlm.nih.gov/pubmed/32903387 http://dx.doi.org/10.1186/s42490-019-0034-8 |
Ejemplares similares
-
Local delivery of dinutuximab from lyophilized silk fibroin foams for treatment of an orthotopic neuroblastoma model
por: Ornell, Kimberly J., et al.
Publicado: (2020) -
Patient-derived xenografts as preclinical neuroblastoma models
por: Braekeveldt, Noémie, et al.
Publicado: (2017) -
Preclinical Models of Neuroblastoma—Current Status and Perspectives
por: Krawczyk, Ewa, et al.
Publicado: (2023) -
Silk Particle Production Based on Silk/PVA Phase Separation Using a Microfabricated Co-flow Device
por: Vargas Montoya, Natalia, et al.
Publicado: (2020) -
Preclinical testing of chimeric antigen receptor T cells in neuroblastoma mouse models
por: Li, Nan, et al.
Publicado: (2021)